Sign In
Buy NVCR
$16.15
+0.330 (+2.09%)
At Close: Jun 03, 2026
Novocure's Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
07:09am, Tuesday, 22'nd Apr 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Lua® has received a CE (Conformité Européenne) Mark for the treatment of adult patients with metastatic non-s
NovoCure (NVCR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:05am, Thursday, 17'th Apr 2025
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why NovoCure Stock Was Withering on Wednesday
03:43pm, Wednesday, 16'th Apr 2025
Cancer-focused biotech NovoCure (NVCR -4.46%) was the focus of a stock price target cut on Wednesday, and investors weren't particularly happy about it.
Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
07:00pm, Tuesday, 04'th Mar 2025
Explore the exciting world of NovoCure (NVCR -1.20%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potenti
NovoCure Q4 2024 Earnings: Strong And Growing Pipeline
01:10pm, Friday, 28'th Feb 2025
NovoCure remains a strong buy due to robust earnings, a growing core business, and a promising pipeline, particularly in lung and pancreatic cancer treatments. Q4 2024 earnings showed strong revenue g
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
05:17am, Friday, 28'th Feb 2025
NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption chal
NovoCure (NVCR) Reports Q4 Earnings: What Key Metrics Have to Say
11:00am, Thursday, 27'th Feb 2025
While the top- and bottom-line numbers for NovoCure (NVCR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compa
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
09:20am, Thursday, 27'th Feb 2025
NovoCure (NVCR) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.45 per share a year ago.
NovoCure Limited (NVCR) Q4 2024 Earnings Conference Call Transcript
09:09am, Thursday, 27'th Feb 2025
NovoCure Limited (NASDAQ:NVCR ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Ingrid Goldberg - Investor Relations Bill Doyle - Chairman Ashley Cordova - Chief Exe
NovoCure Q4 EPS Misses, Revenue Matches
08:53am, Thursday, 27'th Feb 2025
Oncology treatment pioneer NovoCure (NVCR) reported mixed fourth-quarter 2024 earnings on Thursday, Feb. 27. Q4 revenue matched analysts' consensus expectations at $161.3 million and jumped 21% year o
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Thursday, 20'th Feb 2025
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland
04:00am, Wednesday, 22'nd Jan 2025
BAAR, Switzerland--(BUSINESS WIRE)--Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland.
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
07:00am, Monday, 13'th Jan 2025
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update.
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
07:00am, Friday, 03'rd Jan 2025
BAAR, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference.
Why NovoCure Stock Was Winning Big This Week
08:32am, Friday, 06'th Dec 2024
Cancer-targeting biotech NovoCure (NVCR -9.00%) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough. This momentum
